Drug Development Pharma - March 24, 2014
Sobi’s Alprolix gets approval in Canada
Health Canada has approved the company’s treatment for the control and prevention of bleeding episodes and routine prophylaxis. Alprolix has been approved for the treatment of adults and children aged 12 and older, with haemophilia B. This is the first regulatory approval worldwide for Alprolix, which is currently under review by regulatory authorities in several other countries, including […]
Drug Development Pharma - November 20, 2013
Sobi gets EU approval for Kineret
Sobi has announced that the European Commission (EC) has approved Kineret (anakinra) for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS). The decision follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in September 2013, states the company. The approval was based on the outcome […]